These trials, spearheaded by the Institute of Mental Health and the Yong Loo Lin School of Medicine at the National University of Singapore , employ personalised transcranial magnetic stimulation specifically designed for Asian brains.
What sets these trials apart is using a locally developed targeting algorithm created by Dr Ruby Kong and Associate Professor Thomas Yeo from NUS. A total of 20 participants will be recruited for the APIC-TMS trial and 70 for the SPARK-D trial. Dr Tor expressed that it gives them confidence in achieving outcomes similar to SAINT, demonstrating significant improvements in patients’ lives.
The introduction of the Singapore version of the SAINT protocol marks a milestone in the region’s healthcare system, addressing the significant prevalence of depression.Singaporeans are the fastest walkers in the world—why this may be good news for our mental health & ageing issues